Selank: Anxiolytic Peptide from Russian Research

Selank is a synthetic analog of the endogenous neuropeptide tuftsin — a tetrapeptide (Thr-Lys-Pro-Arg) that is a natural fragment of immunoglobulin G and plays a role in immune regulation. Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, selank consists of tuftsin extended with the sequence Pro-Gly-Pro, which significantly increases its stability in the CNS and blood. It was registered as an approved anxiolytic drug in Russia and Ukraine, giving it a clinical status rare among research peptides used internationally.

Development and Russian Clinical Approval

Selank was developed in the 1990s and has been through extensive clinical evaluation in Russia, leading to its registration as Selank (generic name) for the treatment of generalized anxiety disorder and other anxiety-spectrum conditions. Russian registration studies documented efficacy comparable to benzodiazepines without dependency, sedation, or withdrawal — properties that make it pharmacologically novel.

In Western markets, selank is not approved and is sold as a research peptide. However, its Russian clinical approval provides more regulatory validation than most research compounds available.

Mechanism of Action

Selank's anxiolytic mechanism is not fully elucidated but involves several convergent pathways:

GABAergic modulation: Selank increases GABA receptor sensitivity and may enhance GABA turnover in the brain — the same mechanism as benzodiazepines, but without causing receptor downregulation or physical dependency.

Serotonin system: Selank increases expression of serotonin transporters (SERT) and modulates serotonergic neurotransmission in limbic circuits involved in anxiety, mood, and stress response.

BDNF elevation: Studies in rats show selank increases brain-derived neurotrophic factor (BDNF) in the hippocampus and other brain regions — an effect associated with antidepressant action and cognitive enhancement.

Enkephalin system: Selank inhibits the degradation of enkephalins (endogenous opioid peptides) by suppressing enkephalinase activity. Enkephalins modulate stress and anxiety through opioid receptors; their preservation may contribute to selank's anxiolytic effect.

Immune modulation: As a tuftsin analog, selank modulates macrophage and T-cell activity. It has been studied for its effects on cytokine expression, showing normalization of IL-6 and TNF-alpha in various stress models.

Nootropic effects: Selank improves memory consolidation and learning performance in animal models. It increases acetylcholine activity in the hippocampus and improves synaptic plasticity — which may account for the cognitive clarity users report alongside its anxiety reduction.

Clinical Research

Russian anxiety trials: Clinical trials supporting the Russian registration showed selank (500 mcg intranasally twice daily) produced significant reduction in anxiety scores on the Hamilton Anxiety Scale (HAM-A) over 10–14 days, with efficacy maintained through the observation period. Response rates were comparable to medazepam (a benzodiazepine) without sedation.

Stress and adaptation: Studies in patients with mixed anxiety and depressive disorder showed selank improved not only anxiety scores but also cognitive measures including working memory and attention span — the opposite of benzodiazepine effects, which impair cognition.

Neuroprotection: Animal models of chronic stress and neurotoxicity show selank has neuroprotective properties, reducing oxidative stress markers and preserving neuronal architecture in hippocampal tissue.

Dosage and Administration

Standard dosing (intranasal — most common):

250–750 mcg per session intranasally (2–3 drops in each nostril of a 0.15% solution)
1–3 sessions per day
Typical Russian clinical dosing: 500 mcg twice daily for 10–14 day courses

Subcutaneous injection:

250–500 mcg per injection, 1–2 times daily
Provides reliable absorption; preferred when intranasal delivery is difficult
Reconstitute lyophilized selank in saline or sterile water

Intranasal preparation: Selank is most commonly supplied as a 0.15% nasal solution (1.5 mg/mL). Two drops per nostril delivers approximately 100–150 mcg per nostril (200–300 mcg total). Alternatively, inject 250–500 mcg subcutaneously.

Half-life: Approximately 5–10 minutes in blood; its CNS effects persist significantly longer, likely due to receptor-level mechanisms rather than circulating peptide concentrations.

Effects Profile

Selank users consistently describe:

Anxiolytic effect: Reduced generalized anxiety, social anxiety, and performance anxiety — typically noted within 30–60 minutes of a dose
Cognitive clarity: Improved focus, working memory, and verbal fluency (contrasting with the cognitive blunting of benzodiazepines)
Mood stabilization: Subtle antidepressant effect with repeated dosing; normalization of stress reactivity
Energy and motivation: Some users report increased motivation and drive — possibly related to dopaminergic effects
No sedation: Unlike benzodiazepines and most anxiolytics, selank does not cause significant drowsiness at standard doses
No dependency or withdrawal: Discontinuation does not produce rebound anxiety or physical withdrawal symptoms

Comparison to Semax

Selank and semax are often compared as the two flagship Russian nootropic/neuropeptide compounds. Selank is more anxiolytic and calming; semax is more stimulating and cognitively activating. Some users rotate or combine them — semax for cognitive enhancement during productive work, selank for stress management and anxiety reduction.

FAQ

Is selank addictive? Unlike benzodiazepines, selank does not appear to cause physical dependency or withdrawal. Russian clinical data and extended user reports support its non-addictive profile. No cases of selank addiction have been reported in the clinical literature.

How quickly does selank work? Anxiolytic effects are typically noticed within 30–60 minutes of intranasal or subcutaneous administration. The effect builds over several days of consecutive use, with the cognitive enhancement aspect often becoming more pronounced after a week of regular dosing.

Can selank be used for PTSD or social anxiety? While not formally studied for PTSD in controlled trials, selank's GABAergic, serotonergic, and enkephalin-modulating mechanisms are consistent with potential benefit in trauma-related anxiety states. For social anxiety specifically, the combination of anxiety reduction without cognitive impairment makes it theoretically well-suited.

Track your supplements in Optimize.